Please use this identifier to cite or link to this item:
http://repositorio.ufla.br/jspui/handle/1/41526| metadata.artigo.dc.title: | Is the anti-filarial drug diethylcarbamazine useful to treat COVID-19? |
| metadata.artigo.dc.creator: | Abeygunasekera, Anuruddha Jayasinghe, Saroj |
| metadata.artigo.dc.subject: | Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Corona COVID-19 Diethylcarbamazine (DEC) |
| metadata.artigo.dc.publisher: | Elsevier |
| metadata.artigo.dc.date.issued: | Oct-2020 |
| metadata.artigo.dc.identifier.citation: | ABEYGUNASEKERA, A.; JAYASINGHE, S. Is the anti-filarial drug diethylcarbamazine useful to treat COVID-19? Medical Hypotheses, [S.l.], v. 143, Oct. 2020. |
| metadata.artigo.dc.description.abstract: | SARS-CoV-2 virus has resulted in a devastating pandemic of COVID-19. Exploring compounds that could offer a breakthrough in treatment is the need of the hour. Re-positioning cheap, freely available and safe drugs is a priority. The paper proposes evidence for the potential use of diethylcarbamazine (DEC) in the treatment of COVID-19. DEC has inhibitory effects on arachidonic acid metabolism to prostaglandins, little known anti-viral effects on animal retroviruses and demonstrated anti-inflammatory actions in animal models of lung inflammation indicating the need to explore this hypothesis further. We believe this is the first time DEC is being proposed to treat COVID-19. |
| metadata.artigo.dc.identifier.uri: | https://www.sciencedirect.com/science/article/pii/S0306987720305636 http://repositorio.ufla.br/jspui/handle/1/41526 |
| metadata.artigo.dc.language: | en_US |
| Appears in Collections: | FCS - Artigos sobre Coronavirus Disease 2019 (COVID-19) |
Files in This Item:
There are no files associated with this item.
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.